Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 1Rhabdomyosarcoma 1Neurofibromatosis 2 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Medulloblastoma 1Hemangiosarcoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Paclitaxel 7Doxorubicin 5pembrolizumab 4pazopanib 4Gemcitabine 4Bevacizumab 4durvalumab 3Radiotherapy 3Propranolol 3Docetaxel 3regorafenib 2cemiplimab 2Surveys and Questionnaires 2Sunitinib 2Standard of Care 2Nivolumab 2Ifosfamide 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1tremelimumab 1trebananib 1trastuzumab duocarmazine 1talimogene laherparepvec 1talazoparib 1spartalizumab 1sintilimab 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hemangiosarcoma × Vascular Endothelial Growth Factor A × Clear all
NCT00288015 2018-06-25

Bevacizumab in Treating Patients With Angiosarcoma

Northwestern University

Phase 2 Completed
32 enrolled 12 charts
Sarcoma

Hemangiosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡